SeSA-HCPT
SeSA-HCPT is an orally active dual-target inhibitor integrating Topo I and HDAC inhibition. SeSA-HCPT induces potent DNA damage, apoptosis, S-phase arrest in prostate cancer cells. SeSA-HCPT inhibits cancer cells proliferation and migration. SeSA-HCPT impairs homologous recombination by suppressing KIF4A-RAD51 signaling. SeSA-HCPT markedly inhibits CRPC tumor growth with minimal systemic toxicity.
For research use only. We do not sell to patients.
- Formula: C76H76N6O18Se2
- Molecular Weight:1519.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
Topoisomerase I |
KIF4A |
In Vitro
SeSA-HCPT (48 h) exerts superior selective cytotoxicity against AR-positive (LNCaP) and AR-negative (PC3, DU145) human prostate cancer cells with IC50 values of 0.182, 0.198 and 0.175 μM, with minimal toxicity to normal human keratinocyte HaCaT cells (IC50 =5.17 μM)[1].
SeSA-HCPT (200 nM; 24-48 h) induces significantly higher apoptosis in PC3, DU145, and LNCaP human prostate cancer cells[1].
SeSA-HCPT (0.175-5.17 μM; 24 h) induces S-phase cell cycle arrest in PC3, DU145, and LNCaP human prostate cancer cells, with no effect on normal human keratinocyte HaCaT cells, and upregulates Cyclin E expression in PC3 and DU145 cells[1].
SeSA-HCPT (3-10 μM) inhibits Topo1-mediated DNA relaxation, and exhibits binding affinity for the Topo1-DNA complex than HCPT, enhancing its ability to block Topo1 catalytic function[1].
SeSA-HCPT (1.25-5 nM) inhibits HDAC activity in PC3 and DU145 human prostate cancer cells[1].
SeSA-HCPT (1.25-5 nM) induces dose-dependent DNA damage in PC3 and DU145 human prostate cancer cells, as measured by increased γ-H2AX levels[1].
SeSA-HCPT (5 nM; 24-48 h) significantly inhibits proliferation and migration of PC3 and DU145 human prostate cancer cells[1].
SeSA-HCPT (0-50 nM; 24 h) impairs homologous recombination-mediated DNA repair in PC3 and DU145 human prostate cancer cells by downregulating KIF4A and reducing Rad51 recruitment to DNA damage sites, while inducing a DNA damage response, and induces a dose-dependent decrease in KIF4A levels from 0 to 50 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC3, DU145, LNCaP cells
-
Concentration:200 nM (Annexin V/PI staining); 200 nM (Western blot)
-
Incubation Time:48 h (Annexin V/PI staining); 24 h (Western blot)
-
Result:Induced significantly higher levels of apoptosis.
Increased levels of cleaved caspase-3 and p21 in all three cell lines.
-
Cell Line:PC3, DU145, LNCaP, HaCaT cells
-
Concentration:0.175, 0.182, 0.198, 5.17 μM
-
Incubation Time:24 h
-
Result:Induced significant S-phase arrest in PC3, DU145, and LNCaP cells.
Upregulated Cyclin E expression in PC3 and DU145 cells, with no significant changes in Cyclin A2 or Cyclin B levels.
Did not alter cell cycle distribution in HaCaT cells.
-
Cell Line:PC3, DU145 cells
-
Concentration:1, 5, 10, 30, 50 nM
-
Incubation Time:24 h
-
Result:Increased γ-H2AX and phosphorylated ATM
(pS1981-ATM) levels at 5 nM.
Reduced KIF4A levels from 1 to 50 nM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male, 5-week-old, subcutaneous xenograft of PC3 cells)[1]
-
Dosage:20 mg/kg
-
Administration:I.g.; sigle dose
-
Result:Reduced tumor weight and growth significantly.
Reduced Ki67-positive cells pronouncedly.
Increased γ-H2AX-positive cells significantly .
Showed no significant body weight difference compared with controls.
Caused no significant alterations in hepatic (ALT, AST, ALP) or renal (BUN, creatinine) parameters.
Chemical Information
-
Molecular Weight 1519.37
-
Formula C76H76N6O18Se2
-
SMILES
O=C(NC1=CC(COC(CCC(OC2=C(C=C(CN3C4=CC5=C(COC(C5(CC)O)=O)C3=O)C4=N6)C6=CC=C2)=O)=O)=CC=C1)CCCCCC[Se][Se]CCCCCCC(NC7=CC(COC(CCC(OC8=C9C=C%10CN%11C(C%12=C(C=C%11C%10=NC9=CC=C8)C(O)(C(OC%12)=O)CC)=O)=O)=O)=CC=C7)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Acute Systemic Toxicity Study
Acute systemic toxicity studies evaluate adverse effects occurring after a single exposure, or repeated exposure within a short acute window, and the main in vivo readouts are mortality, moribund condition, clinical signs, body-weight change, and gross pathological findings; acute oral toxicity methods were developed to replace classical LD50 testing with reduced-animal designs such as fixed-dose procedure, acute toxic class method, and up-and-down procedure. The fixed-dose procedure classifies acute toxicity by administering predefined dose levels and observing evident toxicity rather than using death as the primary endpoint, whereas the acute toxic class method uses sequential groups of three animals per step and the up-and-down procedure doses animals sequentially to estimate an LD50 with fewer animals than conventional LD50 testing.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
CRISPR-Cas9 HDR knock-in/precise editing
CRISPR-Cas9 HDR knock-in uses a guide RNA to direct Cas9 to a genomic target adjacent to a PAM, where Cas9 creates a double-strand break; if a donor DNA template with homology to the cut region is present, cellular HDR can copy the donor sequence into the genome, producing a precise substitution, tag, reporter, or insertion rather than an indel. The readout is the fraction of alleles or cells carrying the intended donor-derived edit, measured by junction PCR, restriction-fragment analysis, Sanger sequencing, amplicon deep sequencing, flow cytometry for reporter knock-in, or clone genotyping; NHEJ indels and partial or non-HDR insertions are measured in parallel because they compete with or confound precise HDR outcomes.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Subchronic/Chronic Toxicity Study
A subchronic/chronic oral toxicity study detects systemic adverse effects caused by repeated administration of a test article, using mortality, clinical signs, body weight, food/water intake, ophthalmology, urinalysis, hematology, serum biochemistry, organ weights, gross necropsy, and histopathology as integrated readouts. The readout reflects dose-related physiological injury, target-organ pathology, reversibility after recovery, and derivation of NOAEL, LOAEL, or related point-of-departure values when the dataset supports them.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)